Forte Biosciences, a Dallas-based biopharmaceutical company, specializes in dermatology products and is advancing product candidate FB-102 for autoimmune diseases. The company went public on April 13, 2017, and holds a U.S. patent for skin treatment.
Forte Biosciences (FBRX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Forte Biosciences's actual EPS was -$1.37, missing the estimate of -$0.97 per share, resulting in a -41.38% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
